Therapeutic Asset Ratings

462 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Immunoglobulin G4 [221-proline], anti-(human programmed cell death protein 1) (human monoclonal SG001 ?4-chain), disulfide with human monoclonal SG001 ?-chain, dimer Solid Tumor	CSPC Megalith Biopharmaceutical Co.,Ltd.		D (26)
Montanide Isa 51 Solid Tumor	Huashan Hospital		D (26)
Personalized Neoantigen Tumor Vaccine Neoplasm	YueJuan Cheng	N/A	D (26)
qh104 cell Neoplasm	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	N/A	D (26)
xh001 Neoplasm	jianming xu	N/A	D (26)
ft538 Neoplasm	Masonic Cancer Center, University of Minnesota	P1	D (24)
SHR-4685 Neoplasm	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	P1	NR (0)
Hs-It201 Neoplasm	Qingdao Sino-Cell Biomedicine Co., Ltd.	Early P1	NR (0)
cd73/axl.hyposti.car-t cells Neoplasm	Chinese PLA General Hospital	P1/2	NR (0)
Circfam53B Mrna Vaccine Neoplasm	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	P1/2	NR (0)
Fg-B901 Neoplasm	FutureGen Biopharmaceutical (Beijing) Co., Ltd	P1/2	NR (0)
Tumor Polypeptide Pool Induced Dc-Ctl Cell Neoplasm	Zhengzhou Revo-Gene Technology Co., LTD	N/A	NR (0)

Showing 451 to 462 of 462 assets

PreviousPage 19 of 19Next